Skip to main content

Table 5 Unadjusted and adjusted predictors of mortality among patients who were diagnosed with RR-TB between July 2011–June 2012 or between July 2013–July 2014 and who initiated DR-TB treatment in COJ (n = 537)

From: Impact of Xpert MTB/RIF and decentralized care on linkage to care and drug-resistant tuberculosis treatment outcomes in Johannesburg, South Africa

  n/N % HR 95% CI Adjusted HR 95% CI
Gender
 Female 34/258 13.2 Ref Ref Ref Ref
 Male 33/279 11.8 0.78 (0.48–1.26) 0.74 (0.44–1.22)
Age, years
  < 30 17/138 12.3 Ref Ref Ref Ref
 30–45 37/283 13.1 0.92 (0.52–1.64) 0.72 (0.39–1.31)
  ≥ 45 13/119 10.9 0.75 (0.36–1.58) 0.68 (0.32–1.47)
DR-TB classification
 RR-TB by Xpert MTB/RIF 41/237 17.3 1.16 (0.58–2.33) 1.03 (0.50–2.13)
 RIF mono-resistant TB 15/109 13.8 0.87 (0.39–1.97) 0.65 (0.33–1.81)
 MDR-TB 11/191 5.8 Ref Ref Ref Ref
HIV status at initiation
 HIV negative 1/61 1.6 0.14 (0.02–1.01) 0.13 (0.02–0.10)
 HIV positive on ART 53/351 33.6 Ref Ref Ref Ref
 HIV positive not on ART 10/77 12.1 1.49 (0.76–2.94) 1.49 (0.75–2.96)
 HIV status unknown 3/48 6.3 0.38 (0.09–1.54) 0.36 (0.09–1.50)
Registration year
 2011 6/55 10.9 Ref Ref Ref Ref
 2012 11/108 10.2 0.89 (0.33–2.40) 0.88 (0.34–2.59)
 2013 21/166 21.7 1.3 (0.55–3.36) 1.32 (0.52–3.33)
 2014 29/211 13.7 1.45 (0.59–3.51) 1.37 (0.55–3.41)
Time to treatment initiation
 Without delay 31/186 16.7 Ref Ref Ref Ref
 Delayed (deferred) 35/332 10.5 0.89 (0.54–1.45) 0.91 (0.53–1.56)
  1. HR Hazard Ratio, CI Confidence interval, RR-TB Rifampicin resistant TB, MTB Mycobacterium tuberculosis, MDR-TB Multi-drug resistant tuberculosis, XDR-TB Extensively drug-resistant tuberculosis; ART antiretroviral therapy, RIF rifampicin, DR-TB drug resistant TB p < 0.05 bold